Interleukin-1:an important target for perinatal neuroprotection?

作     者：Sharmony B.Kelly Elys Green Rod W.Hunt Claudia A.Nold-Petry Alistair J.Gunn Marcel F.Nold Robert Galinsky Sharmony B.Kelly;Elys Green;Rod W.Hunt;Claudia A.Nold-Petry;Alistair J.Gunn;Marcel F.Nold;Robert Galinsky

作者机构：The Ritchie CentreHudson Institute of Medical ResearchMelbourneVictoriaAustralia Department of Obstetrics and GynaecologyMonash UniversityVictoriaAustralia Department of PediatricsMonash UniversityVictoriaAustralia Monash NewbornMonash Children’s HospitalMelbourneAustralia Department of PhysiologyThe University of AucklandAucklandNew Zealand 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2023年第18卷第1期

页      面：47-50页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

基　　金：supported by the CJ Martin Postdoctoral Fellowship grants from the National Health and Medical Research Council of Australia (1090890 and 1164954) the Cerebral Palsy Alliance, Harold and Cora Brennen Benevolent Trust, Health Research Council of New Zealand (17/601) the Victorian Government’s Operational Infrastructure Support Program (to RG) 

主　　题：brain inflammation interleukin-1 receptor antagonist interleukin-1 interleukin-1β neonatal encephalopathy neuroprotection preterm brain injury 

摘      要：Perinatal inflammation is a significant risk factor for lifelong neurodevelopmental impairments such as cerebral *** clinical and preclinical evidence links the severity and pattern of perinatal inflammation to impaired maturation of white and grey matters and reduced brain *** pathways are involved in the pathogenesis of perinatal ***,studies of human and experimental perinatal encephalopathy have demonstrated a strong causative link between perinatal encephalopathy and excessive production of the pro-inflammatory effector cytokine *** this review,we summarize clinical and preclinical evidence that underpins interleukin-1 as a critical factor in initiating and perpatuating systemic and central nervous system inflammation and subsequent perinatal brain *** also highlight the important role of endogenous interleukin-1 receptor antagonist in mitigating interleukin-1-driven neuroinflammation and tissue damage,and summarize outcomes from clinical and mechanistic animal studies that establish the commercially available interleukin-1 receptor antagonist,anakinra,as a safe and effective therapeutic *** reflect on the evidence supporting clinical translation of interleukin-1 receptor antagonist for infants at the greatest risk of perinatal inflammation and impaired neurodevelopment,and suggest a path to advance interleukin-1 receptor antagonist along the translational path for perinatal neuroprotection.